Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics-Reference-Cited by-同舟云学术

Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics

Published:2020-12-05 Issue:2 Volume:38 Page:1035-1054
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Koller Dora^ORCID,Almenara Susana,Mejía Gina,Saiz-Rodríguez Miriam,Zubiaur Pablo,Román Manuel,Ochoa Dolores,Navares-Gómez Marcos,Santos-Molina Elena,Pintos-Sánchez Elena,Abad-Santos Francisco^ORCID

Funder

H2020 Marie Skłodowska-Curie Actions

Consejería de Educación, Juventud y Deporte, Comunidad de Madrid

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-020-01566-w.pdf

Reference70 articles.

1. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114:169–79.

2. Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry. 1997;58(Suppl 10):37–44.

3. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther. 2010;32(Suppl 1):S3-20.

4. Food and Drug Administration. ABILIFY (aripiprazole) label. Otsuka Pharmaceutical. http://www.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038,021713s030,021729s022,021866s023lbl.pdf. Accessed 1 Jul 2014.

5. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177–93.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment;Pharmacopsychiatry;2024-08-26

2. Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review;Journal of Psychiatric Research;2024-06

3. Combination of UGT1A1 polymorphism and baseline plasma bilirubin levels in predicting the risk of antipsychotic-induced dyslipidemia in schizophrenia patients;Schizophrenia;2024-05-17

4. A Review of Advances in Bioanalytical Methods for the Detection and Quantification of Olanzapine and Its Metabolites in Complex Biological Matrices;Pharmaceuticals;2024-03-21

5. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine;Pharmacological Research;2024-02